Bisphosphonates: Mechanism of Action and Role in Clinical Practice
- 30 September 2008
- journal article
- review article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 83 (9), 1032-1045
- https://doi.org/10.4065/83.9.1032
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ, 2008
- Vitamin D DeficiencyThe New England Journal of Medicine, 2007
- Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate CancerJournal of Clinical Oncology, 2007
- Suppressed Bone Turnover during Alendronate Therapy for High-Turnover OsteoporosisThe New England Journal of Medicine, 2006
- Alendronate or Alfacalcidol in Glucocorticoid-Induced OsteoporosisThe New England Journal of Medicine, 2006
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences of the United States of America, 2006
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseThe New England Journal of Medicine, 2005
- Pharmacokinetics/Pharmacodynamics of BisphosphonatesClinical Pharmacokinetics, 2005
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002